Healthcare provider profile · identity verified

Steven Jacobs, P.A.

Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LAWRENCE, NY · NPI 1063488799

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Steven Jacobs, P.A. received $100.00 in general payments during 2025 across 1 reported records.

GENZYME CORPORATION accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$100.00

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
GENZYME CORPORATION Unresolved — no canonical attribution shown $100.00100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$100.001

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
CERDELGA
Normalized: cerdelga
Drug GENZYME CORPORATION $100.00 1 2025
Source payment records
CEREZYME
Normalized: cerezyme
Biological GENZYME CORPORATION $100.00 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Amlodipine BesylateAmlodipine Besylate11125
Atorvastatin CalciumAtorvastatin Calcium10930
OmeprazoleOmeprazole10021
GabapentinGabapentin8413
Metformin HclMetformin Hcl6917
Levothyroxine SodiumLevothyroxine Sodium6617
LisinoprilLisinopril56suppressed
Quetiapine FumarateQuetiapine Fumarate56suppressed
Albuterol Sulfate HfaAlbuterol Sulfate4713
Diclofenac SodiumDiclofenac Sodium47suppressed
Fluticasone PropionateFluticasone Propionate4620
Metoprolol SuccinateMetoprolol Succinate46suppressed
Trazodone HclTrazodone Hcl45suppressed
Zolpidem TartrateZolpidem Tartrate45suppressed
Losartan PotassiumLosartan Potassium4412
NystatinNystatin44suppressed
FurosemideFurosemide3911
AzithromycinAzithromycin3831
AlprazolamAlprazolam36suppressed
FamotidineFamotidine34suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33suppressed
MirtazapineMirtazapine33suppressed
TrulicityDulaglutide33suppressed
SimvastatinSimvastatin32suppressed
AllopurinolAllopurinol29suppressed
BaclofenBaclofen27suppressed
Pantoprazole SodiumPantoprazole Sodium27suppressed
Rosuvastatin CalciumRosuvastatin Calcium27suppressed
Tramadol HclTramadol Hcl27suppressed
Citalopram HbrCitalopram Hydrobromide25suppressed
ClonazepamClonazepam25suppressed
JardianceEmpagliflozin25suppressed
Single Use SwabAlcohol Antiseptic Pads25suppressed
EliquisApixaban24suppressed
Enalapril MaleateEnalapril Maleate24suppressed
Meclizine HclMeclizine Hcl24suppressed
Tamsulosin HclTamsulosin Hcl24suppressed
AtenololAtenolol23suppressed
LevetiracetamLevetiracetam23suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21suppressed
Bupropion XlBupropion Hcl21suppressed
ClopidogrelClopidogrel Bisulfate21suppressed
Montelukast SodiumMontelukast Sodium20suppressed
Ondansetron OdtOndansetron20suppressed
MyrbetriqMirabegron19suppressed
Pramipexole DihydrochloridePramipexole Di-Hcl18suppressed
HydrocortisoneHydrocortisone17suppressed
MupirocinMupirocin17suppressed
Divalproex SodiumDivalproex Sodium16suppressed
Midodrine HclMidodrine Hcl16suppressed
Doxycycline HyclateDoxycycline Hyclate1514
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15suppressed
GlimepirideGlimepiride15suppressed
JanumetSitagliptin Phos/Metformin Hcl15suppressed
Paroxetine HclParoxetine Hcl15suppressed
Combivent RespimatIpratropium/Albuterol Sulfate14suppressed
HydrochlorothiazideHydrochlorothiazide14suppressed
Hydroxyzine HclHydroxyzine Hcl14suppressed
JanuviaSitagliptin Phosphate14suppressed
Labetalol HclLabetalol Hcl14suppressed
Metoprolol TartrateMetoprolol Tartrate14suppressed
Sertraline HclSertraline Hcl14suppressed
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine13suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl13suppressed
MethylprednisoloneMethylprednisolone1312
Spiriva HandihalerTiotropium Bromide13suppressed
ValsartanValsartan13suppressed
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12suppressed
Duloxetine HclDuloxetine Hcl12suppressed
MounjaroTirzepatide12suppressed
Oxybutynin Chloride ErOxybutynin Chloride12suppressed
Oxycodone HclOxycodone Hcl12suppressed
PhenobarbitalPhenobarbital12suppressed
Potassium ChloridePotassium Chloride12suppressed
VascepaIcosapent Ethyl12suppressed
Azelastine HclAzelastine Hcl11suppressed
Breztri AerosphereBudesonide/Glycopyr/Formoterol11suppressed
Cefpodoxime ProxetilCefpodoxime Proxetil11suppressed
CreonLipase/Protease/Amylase11suppressed
Desmopressin AcetateDesmopressin Acetate11suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl11suppressed
Pravastatin SodiumPravastatin Sodium11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $100.00 · 1 records GENZYME CORPORATION CERDELGA, CEREZYME
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error